#reports #VRME
[VerifyMe](https://eninvs.com/all.php?name=VRME) (Security and Protection Services) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=VRME&q=2024 q1&id=781855)
(2024-05-14, Before Market Open):
- Revenue 0.0% YoY (vs -10.0% in previous quarter and historical rate +69.6%)
- EBITDA 0.0% YoY (vs -14.3% in previous quarter)
- EBITDA margin 50.0% has not changed compared to 50.0% same period last year
- EV/Sales multiple is 0.7x
------------------------------------------------
#reports #UNB
[Union Bankshares](https://eninvs.com/all.php?name=UNB) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169477)
(2024-04-17, After Market Close):
- Revenue -10.0% YoY (vs -10.0% in previous quarter and historical rate -8.3%)
- Net Income -33.3% YoY (vs +500.0% in previous quarter and historical rate -3.3%)
- Net Income margin 22.2% decreased compared to 30.0% same period last year
- P/E multiple is 10.5x compared to historical level (75th percentile) of 24.8x
- P/S multiple is 3.1x
- Price to book: 1.8x
The company showed EPS +$0.53 per share. At the opening of the session the share price went up +0.1% vs S&P500 +0.2%
------------------------------------------------
#reports #TISI
[Team](https://eninvs.com/all.php?name=TISI) (Specialty Business Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169476)
(2023-05-11, After Market Close):
- Revenue -1.0% YoY (vs +1.4% in previous quarter and historical rate +2.4%)
- Net Income margin -8.5% increased compared to -12.4% same period last year
- P/S multiple is 0.0x
- Price to book: 0.6x
At the opening of the session the share price went down -0.2% vs S&P500 +0.2%
------------------------------------------------
#reports #STRS
[Stratus Properties](https://eninvs.com/all.php?name=STRS) (Real Estate — Diversified) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169472)
(2024-05-13, Before Market Open):
- Revenue +150.0% YoY (vs -69.2% in previous quarter and historical rate +7.8%)
- EBITDA margin 106.7% increased compared to -83.3% same period last year
- EV/EBITDA multiple is 45.1x compared to historical level (75th percentile) of 81.6x
- EV/Sales multiple is 15.0x
The company showed EPS +$0.56 per share. At the opening of the session the share price went down -4.7% vs S&P500 +0.2%
------------------------------------------------
#reports #SSTI
[ShotSpotter](https://eninvs.com/all.php?name=SSTI) (Software — Application) reported for 2024 q1
(2024-05-14, After Market Close):
- Revenue +19.0% YoY (vs -67.9% in previous quarter and historical rate +30.7%)
- Net Debt decreased by $3.0 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.4% of market cap
- EV/EBITDA multiple is 24.8x compared to historical level (75th percentile) of 67.6x
- EV/Sales multiple is 1.8x
------------------------------------------------
#reports #PXLW
[Pixelworks](https://eninvs.com/all.php?name=PXLW) (Semiconductors) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=PXLW&q=2024 q1&id=781900)
(2024-05-14, After Market Close):
- Revenue +60.0% YoY (vs +17.6% in previous quarter and historical rate +29.7%)
- EBITDA margin -25.0% increased compared to -90.0% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 11.3% of market cap
- EV/Sales multiple is 1.7x
------------------------------------------------
#reports #PRPO
[Precipio](https://eninvs.com/all.php?name=PRPO) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169505)
(2023-11-13, After Market Close):
- Revenue 0.0% YoY (vs +33.3% in previous quarter and historical rate +48.6%)
- EBITDA margin -33.3% increased compared to -66.7% same period last year
- EV/Sales multiple is 9.9x
At the opening of the session the share price went down -7.1% vs S&P500 +1.0%
------------------------------------------------
#reports #POAI
[Predictive Oncology](https://eninvs.com/all.php?name=POAI) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169528)
(2023-05-17, After Market Close):
- Revenue +75.0% YoY (vs -7.7% in previous quarter and historical rate +79.7%)
- EBITDA margin -970.0% decreased compared to -22.5% same period last year
- Net Debt increased by $3.4 bln over the past reporting period (2709.1% of market cap)
- FCF (LTM) -$13.7 bln (negative), 10817.5% of market cap
- EV/EBITDA multiple is 0.3x compared to historical level (75th percentile) of 1.5x
- EV/Sales multiple is -2.3x
------------------------------------------------
#reports #PMD
[Psychemedics Corporation](https://eninvs.com/all.php?name=PMD) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169480)
(2024-05-13, Before Market Open):
- Revenue -16.7% YoY (vs -16.7% in previous quarter and historical rate +9.8%)
- EBITDA margin -20.0% decreased compared to -16.7% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (6.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 6.8% of market cap
- EV/Sales multiple is 0.7x
------------------------------------------------
#reports #PBH
[Prestige Consumer Healthcare](https://eninvs.com/all.php?name=PBH) (Medicines manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=PBH&q=2024 q1&id=781897)
(2024-05-14, After Market Close):
- Revenue -3.1% YoY (vs +2.5% in previous quarter and historical rate +6.3%)
- EBITDA margin 32.5% increased compared to -95.5% same period last year
- Net Debt decreased by $56.0 mln over the past reporting period (1.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 5.2% of market cap
- EV/EBITDA multiple is 12.5x compared to historical level (75th percentile) of 466.6x
- EV/Sales multiple is 4.1x
On post-market the stock shows a decrease by -7.7%
------------------------------------------------
#reports #OVLY
[Oak Valley Bancorp](https://eninvs.com/all.php?name=OVLY) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169531)
(2024-04-18, Before Market Open):
- Revenue -15.0% YoY (vs -15.0% in previous quarter and historical rate +14.8%)
- Net Income -41.7% YoY (vs -33.3% in previous quarter and historical rate +46.6%)
- Net Income margin 41.2% decreased compared to 60.0% same period last year
- P/E multiple is 5.6x compared to historical level (75th percentile) of 8.2x
- P/S multiple is 2.8x
- Price to book: 1.2x
The company showed EPS +$0.69 per share. At the opening of the session the share price went up +0.3% vs S&P500 +0.2%
------------------------------------------------
#reports #NSYS
[Nortech Systems](https://eninvs.com/all.php?name=NSYS) (Electronic Components) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169412)
(2024-05-16, After Market Close):
- Revenue -2.9% YoY (vs 0.0% in previous quarter and historical rate +13.0%)
- EBITDA 0.0% YoY (vs -62.5% in previous quarter and historical rate +49.0%)
- EBITDA margin 5.9% increased compared to 5.7% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (4.8% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.8% of market cap
- EV/EBITDA multiple is 5.9x compared to historical level (75th percentile) of 4.8x
- EV/Sales multiple is 0.4x
The company showed EPS +$2942.31 per share
------------------------------------------------
#reports #NAII
[Natural Alternatives International](https://eninvs.com/all.php?name=NAII) (Packaged Foods) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169479)
(2024-05-13, After Market Close):
- Revenue -24.2% YoY (vs -40.5% in previous quarter and historical rate +6.5%)
- EBITDA margin -4.0% increased compared to -6.1% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (5.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 44.7% of market cap
- EV/EBITDA multiple is 10.1x compared to historical level (75th percentile) of 4.9x
- EV/Sales multiple is 0.4x
------------------------------------------------
#reports #MTEX
[Mannatech](https://eninvs.com/all.php?name=MTEX) (Household and Personal Products) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169389)
(2024-05-13, Before Market Open):
- Revenue -14.7% YoY (vs -2.9% in previous quarter and historical rate -0.2%)
- EBITDA margin 3.4% increased compared to 2.9% same period last year
- EV/EBITDA multiple is 1.7x compared to historical level (75th percentile) of 2.8x
- EV/Sales multiple is 0.1x
At the opening of the session the share price went down -7.4% vs S&P500 +0.2%
------------------------------------------------
#reports #IRIX
[IRIDEX Corporation](https://eninvs.com/all.php?name=IRIX) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=IRIX&q=2024 q1&id=781891)
(2024-05-14, After Market Close):
- Revenue -14.3% YoY (vs -20.0% in previous quarter and historical rate +10.9%)
- EBITDA margin -25.0% decreased compared to -14.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 12.0% of market cap
- EV/Sales multiple is 0.9x
------------------------------------------------
#reports #INTZ
[Intrusion](https://eninvs.com/all.php?name=INTZ) (Software — Infrastructure) reported for 2024 q1
(2024-05-15, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate -16.7%)
- EBITDA margin -200.0% increased compared to -400.0% same period last year
- EV/Sales multiple is 4.3x
------------------------------------------------
#reports #DMTK
[DermTech](https://eninvs.com/all.php?name=DMTK) (Medicine services provider) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DMTK&q=2024 q1&id=781886)
(2024-05-14, After Market Close):
- Revenue +33.3% YoY (vs +33.3% in previous quarter and historical rate +54.9%)
- EBITDA margin -475.0% increased compared to -1033.3% same period last year
- Net Debt increased by $16.0 mln over the past reporting period (72.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 216.8% of market cap
- EV/Sales multiple is 2.3x
------------------------------------------------
#reports #DCTH
[Delcath Systems](https://eninvs.com/all.php?name=DCTH) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DCTH&q=2024 q1&id=781831)
(2024-05-14, Before Market Open):
- Revenue +200.0% YoY (vs 0.0% in previous quarter and historical rate +62.5%)
- EBITDA margin -333.3% increased compared to -800.0% same period last year
- Net Debt increased by $7.0 mln over the past reporting period (4.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.5% of market cap
- EV/Sales multiple is 40.2x
At the opening of the session the share price went up +11.3% vs S&P500 0.0%
------------------------------------------------
#reports #BLIN
[Bridgeline Digital](https://eninvs.com/all.php?name=BLIN) (Software — Infrastructure) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BLIN&q=2024 q1&id=781878)
(2024-05-14, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +19.4%)
- EV/Sales multiple is 0.6x
------------------------------------------------
#reports #ACOR
[Acorda Therapeutics](https://eninvs.com/all.php?name=ACOR) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169502)
(2023-08-08, After Market Close):
- Revenue -9.1% YoY (vs +22.6% in previous quarter and historical rate -7.7%)
- EBITDA margin -95.0% decreased compared to -13.6% same period last year
- Net Debt increased by $26.0 mln over the past reporting period (161.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 248.6% of market cap
- EV/Sales multiple is 1.8x
At the opening of the session the share price went down -2.2% vs S&P500 0.0%
------------------------------------------------
#reports #AC
[Associated Capital Group](https://eninvs.com/all.php?name=AC) (Capital Markets) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=AC&q=2024 q1&id=780759)
(2024-05-09, After Market Close):
- Revenue +50.0% YoY (vs -25.0% in previous quarter and historical rate +1.3%)
- Net Income -22.2% YoY (vs +14.3% in previous quarter and historical rate -23.9%)
- Net Income margin 466.7% decreased compared to 900.0% same period last year
- P/E multiple is 25.2x compared to historical level (75th percentile) of 24.0x
- P/S multiple is 56.2x
- Price to book: 0.8x
The company showed EPS +$0.64 per share. At the opening of the session the share price went down -0.3% vs S&P500 +0.2%
------------------------------------------------
#reports #ABSI
[Absci Corporation](https://eninvs.com/all.php?name=ABSI) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169374)
(2024-05-14, Before Market Open):
- EBITDA margin 6800.0% increased compared to -2100.0% same period last year
- Net Debt decreased by $65.0 mln over the past reporting period (13.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 8.5% of market cap
- EV/Sales multiple is 83.3x
At the opening of the session the share price went down -9.1% vs S&P500 0.0%
------------------------------------------------
#reports #SE
@ gaming
[Sea](https://eninvs.com/all.php?name=SE) (Electronic Gaming and Multimedia) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=SE&q=2024 q1&id=781851)
(2024-05-14, Before Market Open):
- Revenue +22.8% YoY (vs +4.8% in previous quarter and historical rate +45.5%)
- EBITDA -29.8% YoY (vs -122.8% in previous quarter and historical rate +37.3%)
- EBITDA margin 3.4% decreased compared to 6.0% same period last year
- Net Debt decreased by $213.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) -$1.0 bln (negative), 2.8% of market cap
- EV/EBITDA multiple is 121.6x compared to historical level (75th percentile) of 82.6x
- EV/Sales multiple is 2.6x
------------------------------------------------
#reports #BABA
@ china , @ e-commerce
[Alibaba](https://eninvs.com/all.php?name=BABA) (Chinese e-commerce giant) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BABA&q=2024 q1&id=781826)
(2024-05-14, Before Market Open):
- Revenue +1.4% YoY (vs +2.1% in previous quarter and historical rate +8.4%)
- EBITDA -8.2% YoY (vs -25.4% in previous quarter and historical rate +13.8%)
- EBITDA margin 10.8% decreased compared to 11.9% same period last year
- Net Debt increased by $6.6 bln over the past reporting period (3.2% of market cap)
- FCF (LTM) -$3.7 bln (negative), 1.8% of market cap
- EV/EBITDA multiple is 8.2x compared to historical level (75th percentile) of 14.7x
- EV/Sales multiple is 1.3x
At the opening of the session the share price went down -5.9% vs S&P500 0.0%
------------------------------------------------
#reports #OPTN
[OptiNose](https://eninvs.com/all.php?name=OPTN) (Drug Manufacturers — Specialty and Generic) reported for 2024 q1
(2024-05-14, Before Market Open):
- Revenue +25.0% YoY (vs -4.8% in previous quarter and historical rate +28.3%)
- EBITDA margin -53.3% increased compared to -116.7% same period last year
- Net Debt increased by $22.0 mln over the past reporting period (16.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 8.4% of market cap
- EV/Sales multiple is 2.0x
At the opening of the session the share price went down -5.1% vs S&P500 0.0%
------------------------------------------------
#reports #HYFM
[Hydrofarm Holdings Group, Inc.](https://eninvs.com/all.php?name=HYFM) (Farm and Heavy Construction Machinery) reported for 2024 q1
(2024-05-14, Before Market Open):
- Revenue -12.9% YoY (vs -23.0% in previous quarter and historical rate -18.2%)
- EBITDA +133.3% YoY (vs +1500.0% in previous quarter and historical rate +5.6%)
- EBITDA margin 13.0% increased compared to 4.8% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 45.1% of market cap
- EV/EBITDA multiple is 18.0x compared to historical level (75th percentile) of 185.1x
- EV/Sales multiple is 0.9x
At the opening of the session the share price went up +2.1% vs S&P500 0.0%
------------------------------------------------
#reports #GRNQ
[Greenpro Capital](https://eninvs.com/all.php?name=GRNQ) (Consulting Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169352)
(2022-05-10):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +50.0%)
- Net Debt increased by $1.0 mln over the past reporting period (10.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 10.8% of market cap
- EV/Sales multiple is 2.1x
The company showed EPS -$0.04 per share
------------------------------------------------
#reports #DTIL
[Precision BioSciences](https://eninvs.com/all.php?name=DTIL) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169340)
(2024-05-08, Before Market Open):
- Revenue +100.0% YoY (vs -72.0% in previous quarter and historical rate +63.4%)
- EBITDA margin -77.8% increased compared to -255.6% same period last year
- Net Debt decreased by $21.0 mln over the past reporting period (1.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.2% of market cap
- EV/Sales multiple is 20.5x
The company showed EPS +$0.00 per share. At the opening of the session the share price went up +4.5% vs S&P500 -0.4%
------------------------------------------------
#reports #CAAS
[China Automotive Systems](https://eninvs.com/all.php?name=CAAS) (Auto Parts) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169368)
(2024-05-14, Before Market Open):
- Revenue -2.1% YoY (vs +23.3% in previous quarter and historical rate +25.4%)
- EBITDA +15.4% YoY (vs +280.0% in previous quarter and historical rate +71.5%)
- EBITDA margin 10.8% increased compared to 9.2% same period last year
- Net Debt increased by $55.0 mln over the past reporting period (53.1% of market cap)
- FCF (LTM) +$0.0 bln (positive), 18.4% of market cap
- EV/EBITDA multiple is 0.8x compared to historical level (75th percentile) of 3.7x
- EV/Sales multiple is 0.1x
At the opening of the session the share price went up +3.5% vs S&P500 0.0%
------------------------------------------------
#reports #BIOL
[BIOLASE](https://eninvs.com/all.php?name=BIOL) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169325)
(2023-11-09, After Market Close):
- Revenue 0.0% YoY (vs -7.1% in previous quarter and historical rate +31.0%)
- EBITDA margin -40.0% increased compared to -50.0% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (2028.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 5071.5% of market cap
- EV/Sales multiple is 1.0x
At the opening of the session the share price went down -23.8% vs S&P500 -0.5%
------------------------------------------------
#reports #ASRV
[AmeriServ Financial](https://eninvs.com/all.php?name=ASRV) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169330)
(2024-04-16, Before Market Open):
- Revenue -10.0% YoY (vs -10.0% in previous quarter and historical rate -11.5%)
- Net Income 0.0% YoY (vs -600.0% in previous quarter and historical rate +5.4%)
- Net Income margin 22.2% increased compared to 20.0% same period last year
- P/S multiple is 1.3x
- Price to book: 0.4x
The company showed EPS +$0.11 per share. At the opening of the session the share price went up +3.5% vs S&P500 +0.1%
------------------------------------------------
#reports #GEO
@ REITs
[The GEO Group](https://eninvs.com/all.php?name=GEO) (REIT — Healthcare Facilities) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169256)
(2024-05-07, Before Market Open):
- Revenue -0.3% YoY (vs -2.1% in previous quarter and historical rate +1.4%)
- EBITDA -11.2% YoY (vs -17.9% in previous quarter and historical rate +5.9%)
- EBITDA margin 18.3% decreased compared to 20.6% same period last year
- Net Debt decreased by $58.0 mln over the past reporting period (3.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 7.2% of market cap
- EV/EBITDA multiple is 7.0x compared to historical level (75th percentile) of 7.3x
- EV/Sales multiple is 1.4x
The company showed EPS +$0.14 per share. At the opening of the session the share price went down -5.3% vs S&P500 +0.1%
------------------------------------------------
#reports #XGN
[Exagen](https://eninvs.com/all.php?name=XGN) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169273)
(2024-05-13, Before Market Open):
- Revenue +27.3% YoY (vs +7.7% in previous quarter and historical rate +11.1%)
- EBITDA margin -21.4% increased compared to -63.6% same period last year
- Net Debt increased by $9.0 mln over the past reporting period (32.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 50.0% of market cap
- EV/Sales multiple is 0.4x
The company showed EPS -$0.19 per share. At the opening of the session the share price went up +0.6% vs S&P500 +0.2%
------------------------------------------------
#reports #VNRX
[VolitionRx Limited](https://eninvs.com/all.php?name=VNRX) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169295)
(2024-05-13, After Market Close):
- Revenue +14.7% YoY (vs +103.3% in previous quarter and historical rate +109.8%)
- EBITDA margin -4721.5% increased compared to -5848.7% same period last year
- Net Debt increased by $8.6 bln over the past reporting period (17626.1% of market cap)
- FCF (LTM) +$1.1 bln (positive), 2287.4% of market cap
- EV/EBITDA multiple is 0.2x compared to historical level (75th percentile) of 0.5x
- EV/Sales multiple is -8.8x
------------------------------------------------
#reports #URGN
[UroGen Pharma](https://eninvs.com/all.php?name=URGN) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169272)
(2024-05-13, Before Market Open):
- Revenue +11.8% YoY (vs +33.3% in previous quarter and historical rate +67.5%)
- EBITDA margin -136.8% increased compared to -158.8% same period last year
- Net Debt decreased by $28.0 mln over the past reporting period (6.4% of market cap)
- FCF (LTM) -$0.1 bln (negative), 22.7% of market cap
- EV/Sales multiple is 4.4x
At the opening of the session the share price went down -14.4% vs S&P500 +0.2%
------------------------------------------------
#reports #TKNO
[Alpha Teknova, Inc.](https://eninvs.com/all.php?name=TKNO) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169293)
(2024-05-13, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +3.2%)
- EBITDA margin -77.8% increased compared to -88.9% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (16.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 2.0% of market cap
- EV/Sales multiple is 1.6x
------------------------------------------------
#reports #TBPH
[Theravance Biopharma](https://eninvs.com/all.php?name=TBPH) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=TBPH&q=2024 q1&id=781653)
(2024-05-13, After Market Close):
- Revenue -68.1% YoY (vs +20.0% in previous quarter and historical rate +23.9%)
- EBITDA margin -73.3% decreased compared to -53.2% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 20.1% of market cap
- EV/EBITDA multiple is 23.2x compared to historical level (75th percentile) of 1074.0x
- EV/Sales multiple is 6.2x
------------------------------------------------
#reports #STXS
[Stereotaxis](https://eninvs.com/all.php?name=STXS) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=STXS&q=2024 q1&id=781651)
(2024-05-13, After Market Close):
- Revenue 0.0% YoY (vs -28.6% in previous quarter and historical rate +1.7%)
- EBITDA margin -71.4% increased compared to -85.7% same period last year
- Net Debt increased by $22.0 mln over the past reporting period (12.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.9% of market cap
- EV/Sales multiple is 6.1x
On post-market the stock shows a growth by +6.5%
------------------------------------------------
#reports #SND
[Smart Sand](https://eninvs.com/all.php?name=SND) (Oil and Gas Equipment and Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169291)
(2024-05-13, After Market Close):
- Revenue +1.2% YoY (vs -16.2% in previous quarter and historical rate +50.7%)
- EBITDA margin 1.2% increased compared to -1.2% same period last year
- Net Debt decreased by $38.0 mln over the past reporting period (42.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 4.5% of market cap
- EV/EBITDA multiple is 31.9x compared to historical level (75th percentile) of 21.3x
- EV/Sales multiple is 0.4x
------------------------------------------------
#reports #SENS
[Senseonics](https://eninvs.com/all.php?name=SENS) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169289)
(2024-05-13, After Market Close):
- Revenue +25.0% YoY (vs +33.3% in previous quarter and historical rate +54.4%)
- EBITDA -120.9% YoY (vs -45.9% in previous quarter and historical rate +20.6%)
- EBITDA margin -360.0% decreased compared to 2150.0% same period last year
- Net Debt increased by $6.0 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 10.7% of market cap
- EV/Sales multiple is 10.6x
------------------------------------------------
#reports #QUIK
[QuickLogic Corporation](https://eninvs.com/all.php?name=QUIK) (Semiconductors) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=QUIK&q=2024 q1&id=781646)
(2024-05-13, After Market Close):
- Revenue +50.0% YoY (vs +75.0% in previous quarter and historical rate +37.9%)
- Net Debt decreased by $6.0 mln over the past reporting period (3.4% of market cap)
- EV/EBITDA multiple is 56.0x compared to historical level (75th percentile) of 112.0x
- EV/Sales multiple is 7.3x
------------------------------------------------
#reports #NSPR
[InspireMD](https://eninvs.com/all.php?name=NSPR) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169298)
(2024-05-14, Before Market Open):
- Revenue +100.0% YoY (vs +100.0% in previous quarter and historical rate +66.7%)
- EBITDA margin -350.0% increased compared to -400.0% same period last year
- Net Debt increased by $5.0 mln over the past reporting period (26.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 159.5% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 1.0x
- EV/Sales multiple is -1.8x
------------------------------------------------
#reports #LIVE
[Live Ventures](https://eninvs.com/all.php?name=LIVE) (Specialty Retail) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=LIVE&q=2024 q1&id=645304)
(2023-05-11, Before Market Open):
- Revenue +30.8% YoY (vs +71.0% in previous quarter and historical rate +56.2%)
- EBITDA -66.7% YoY (vs -28.6% in previous quarter and historical rate +2.8%)
- EBITDA margin 2.5% decreased compared to 9.9% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (9.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 59.2% of market cap
- EV/EBITDA multiple is 13.0x compared to historical level (75th percentile) of 9.7x
- EV/Sales multiple is 0.7x
At the opening of the session the share price went down -4.0% vs S&P500 -0.1%
------------------------------------------------
#reports #KFFB
[Kentucky First Federal Bancorp](https://eninvs.com/all.php?name=KFFB) (Banks — Regional) reported for 2024 q1
(2024-05-13, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate -6.9%)
- P/E multiple is 28.8x compared to historical level (75th percentile) of 49.0x
- P/S multiple is 3.6x
- Price to book: 0.6x
------------------------------------------------
#reports #IDN
[Intellicheck](https://eninvs.com/all.php?name=IDN) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=IDN&q=2024 q1&id=781641)
(2024-05-13, After Market Close):
- Revenue +25.0% YoY (vs 0.0% in previous quarter and historical rate +28.6%)
- EV/Sales multiple is 2.3x
------------------------------------------------
#reports #DIS
[Walt Disney](https://eninvs.com/all.php?name=DIS) (Entertainment media conglomerate) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=161905)
(2024-02-07, After Market Close):
- Revenue +1.2% YoY (vs +0.2% in previous quarter and historical rate +16.2%)
- EBITDA -39.7% YoY (vs +17.7% in previous quarter and historical rate +26.2%)
- EBITDA margin 9.4% decreased compared to 15.7% same period last year
- Net Debt decreased by $1.1 bln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$6.5 bln (positive), 3.3% of market cap
- EV/EBITDA multiple is 24.0x compared to historical level (75th percentile) of 33.8x
- EV/Sales multiple is 2.7x
The company showed EPS +$1.04 per share. At the opening of the session the share price went up +8.0% vs S&P500 0.0%
------------------------------------------------
#reports #DERM
[Journey Medical Corporation](https://eninvs.com/all.php?name=DERM) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DERM&q=2024 q1&id=781638)
(2024-05-13, After Market Close):
- Revenue +8.3% YoY (vs -6.3% in previous quarter and historical rate +0.5%)
- EBITDA margin -84.6% decreased compared to -83.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) +$0.0 bln (positive), 22.8% of market cap
- EV/Sales multiple is 0.7x
------------------------------------------------
#reports #CARA
[Cara Therapeutics](https://eninvs.com/all.php?name=CARA) (Medicines Developer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169279)
(2024-05-13, After Market Close):
- Revenue -66.7% YoY (vs 0.0% in previous quarter and historical rate +21.4%)
- EBITDA margin -1500.0% decreased compared to -450.0% same period last year
- Net Debt increased by $30.0 mln over the past reporting period (74.4% of market cap)
- FCF (LTM) -$0.1 bln (negative), 124.0% of market cap
- EV/EBITDA multiple is 0.2x compared to historical level (75th percentile) of 0.4x
- EV/Sales multiple is -1.3x
------------------------------------------------
#reports #AP
[Ampco-Pittsburgh Corporation](https://eninvs.com/all.php?name=AP) (Metal Fabrication) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169277)
(2024-05-13, After Market Close):
- Revenue +4.8% YoY (vs +14.9% in previous quarter and historical rate +9.9%)
- EBITDA -16.7% YoY (vs -1950.0% in previous quarter and historical rate +33.5%)
- EBITDA margin 4.5% decreased compared to 5.7% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 21.7% of market cap
- EV/EBITDA multiple is 2.8x compared to historical level (75th percentile) of 18.9x
- EV/Sales multiple is 0.4x
------------------------------------------------
#reports #AKYA
[Akoya Biosciences, Inc.](https://eninvs.com/all.php?name=AKYA) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=AKYA&q=2024 q1&id=781630)
(2024-05-13, After Market Close):
- Revenue -14.3% YoY (vs +23.8% in previous quarter and historical rate +24.7%)
- EBITDA margin -105.6% decreased compared to -71.4% same period last year
- Net Debt increased by $21.0 mln over the past reporting period (10.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 7.9% of market cap
- EV/Sales multiple is 2.4x
------------------------------------------------
#reports #AGYS
[Agilysys](https://eninvs.com/all.php?name=AGYS) (Software — Application) reported for 2024 q1
(2024-05-13, After Market Close):
- Revenue +17.0% YoY (vs +22.0% in previous quarter and historical rate +20.6%)
- EBITDA 0.0% YoY (vs +100.0% in previous quarter)
- EBITDA margin 6.5% decreased compared to 7.5% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 2.8% of market cap
- EV/EBITDA multiple is 119.9x compared to historical level (75th percentile) of 137.3x
- EV/Sales multiple is 8.6x
------------------------------------------------
#reports #TSLA
@ artificial-intelligence , @ electric-vehicles
[Tesla](https://eninvs.com/all.php?name=TSLA) (Vehicles manufacturer) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=162090)
(2024-01-24, After Market Close):
- Revenue -8.7% YoY (vs +3.5% in previous quarter and historical rate +42.5%)
- EBITDA -34.9% YoY (vs -30.1% in previous quarter and historical rate +56.2%)
- EBITDA margin 11.3% decreased compared to 15.9% same period last year
- Net Debt increased by $22.9 bln over the past reporting period (4.2% of market cap)
- FCF (LTM) +$4.3 bln (positive), 0.8% of market cap
- EV/EBITDA multiple is 42.4x compared to historical level (75th percentile) of 98.2x
- EV/Sales multiple is 5.5x
The company showed EPS +$2.27 per share. At the opening of the session the share price went down -8.7% vs S&P500 +0.2%
------------------------------------------------
#reports #HUYA
@ china , @ gaming
[HUYA](https://eninvs.com/all.php?name=HUYA) (Entertainment) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=HUYA&q=2024 q1&id=781612)
(2024-03-19, Before Market Open):
- Revenue -26.8% YoY (vs -29.5% in previous quarter and historical rate -17.1%)
- EBITDA +27.3% YoY (vs -3200.0% in previous quarter and historical rate +13.9%)
- EBITDA margin 6.7% increased compared to 3.9% same period last year
- Net Debt increased by $43.0 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) -$0.4 bln (negative), 38.6% of market cap
- EV/EBITDA multiple is 3.5x compared to historical level (75th percentile) of 155.0x
- EV/Sales multiple is 0.2x
At the opening of the session the share price went down -8.9% vs S&P500 -0.2%
------------------------------------------------
#reports #XPER
[Xperi](https://eninvs.com/all.php?name=XPER) (Semiconductor Equipment and Materials) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168842)
(2024-05-08, After Market Close):
- Revenue -6.3% YoY (vs +0.7% in previous quarter and historical rate -11.8%)
- EBITDA margin -24.4% decreased compared to -23.6% same period last year
- Net Debt increased by $43.0 mln over the past reporting period (10.2% of market cap)
- FCF (LTM) +$0.0 bln (positive), 9.5% of market cap
- EV/Sales multiple is 0.7x
The company showed EPS +$0.01 per share. At the opening of the session the share price went down -5.2% vs S&P500 0.0%
------------------------------------------------
#reports #VZIO
[VIZIO Holding Corp.](https://eninvs.com/all.php?name=VZIO) (Consumer Electronics) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=VZIO&q=2024 q1&id=780535)
(2024-05-08, After Market Close):
- Revenue -0.8% YoY (vs -5.8% in previous quarter and historical rate -9.1%)
- EBITDA margin -5.4% decreased compared to -0.6% same period last year
- Net Debt increased by $18.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) +$0.0 bln (positive), 0.2% of market cap
- EV/EBITDA multiple is 169.8x compared to historical level (75th percentile) of 65.8x
- EV/Sales multiple is 1.0x
The company showed EPS -$0.06 per share. At the opening of the session the share price went down -1.5% vs S&P500 0.0%
------------------------------------------------
#reports #USPH
[U.S. Physical Therapy](https://eninvs.com/all.php?name=USPH) (Medical services provider) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169238)
(2024-05-07, After Market Close):
- Revenue +4.7% YoY (vs +9.9% in previous quarter and historical rate +14.2%)
- EBITDA -14.3% YoY (vs -72.7% in previous quarter and historical rate -3.2%)
- EBITDA margin 11.5% decreased compared to 14.1% same period last year
- Net Debt decreased by $1.8 bln over the past reporting period (127.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 9.8% of market cap
- EV/EBITDA multiple is 48.4x compared to historical level (75th percentile) of 45.3x
- EV/Sales multiple is 5.1x
The company showed EPS +$0.46 per share. At the opening of the session the share price went down -2.8% vs S&P500 -0.4%
------------------------------------------------
#reports #SUPN
[Supernus Pharmaceuticals](https://eninvs.com/all.php?name=SUPN) (Pharmaceutical manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=SUPN&q=2024 q1&id=780506)
(2024-05-08, After Market Close):
- Revenue -6.5% YoY (vs -1.8% in previous quarter and historical rate +3.2%)
- EBITDA -19.5% YoY (vs -57.1% in previous quarter and historical rate -9.6%)
- EBITDA margin 22.9% decreased compared to 26.6% same period last year
- Net Debt decreased by $43.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) +$0.5 bln (positive), 32.4% of market cap
- EV/EBITDA multiple is 19.1x compared to historical level (75th percentile) of 19.4x
- EV/Sales multiple is 2.2x
The company showed EPS +$0.00 per share. At the opening of the session the share price went up +0.7% vs S&P500 0.0%
------------------------------------------------
#reports #STE
[STERIS](https://eninvs.com/all.php?name=STE) (Medical equipment supplier) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=STE&q=2024 q1&id=780502)
(2024-05-08, After Market Close):
- Revenue +2.5% YoY (vs +14.8% in previous quarter and historical rate +22.2%)
- EBITDA -5.6% YoY (vs +61.5% in previous quarter and historical rate +34.2%)
- EBITDA margin 30.7% decreased compared to 33.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 0.6% of market cap
- EV/EBITDA multiple is 15.7x compared to historical level (75th percentile) of 28.8x
- EV/Sales multiple is 4.2x
The company showed EPS +$1.54 per share. At the opening of the session the share price went up +6.1% vs S&P500 0.0%
------------------------------------------------
#reports #SONX
[Sonendo, Inc.](https://eninvs.com/all.php?name=SONX) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169041)
(2024-05-08, After Market Close):
- Revenue -36.4% YoY (vs -83.3% in previous quarter and historical rate -14.6%)
- EBITDA margin -142.9% decreased compared to -127.3% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (23.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 294.0% of market cap
- EV/Sales multiple is -0.0x
The company showed EPS -$0.07 per share. At the opening of the session the share price went up +7.3% vs S&P500 0.0%
------------------------------------------------
#reports #SNEX
[StoneX Group](https://eninvs.com/all.php?name=SNEX) (Financial service provider) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168957)
(2024-05-08, After Market Close):
- Revenue +36.8% YoY (vs +50.4% in previous quarter and historical rate +75.5%)
- Net Income +26.2% YoY (vs -10.4% in previous quarter and historical rate +37.4%)
- Net Income margin 0.2% has not changed compared to 0.3% same period last year
- P/E multiple is 9.5x compared to historical level (75th percentile) of 8.7x
- P/S multiple is 0.0x
- Price to book: 1.5x
The company showed EPS +$1.63 per share. At the opening of the session the share price went up +0.1% vs S&P500 0.0%
------------------------------------------------
#reports #SMSI
[Smith Micro Software](https://eninvs.com/all.php?name=SMSI) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=SMSI&q=2024 q1&id=780494)
(2024-05-08, After Market Close):
- Revenue -45.5% YoY (vs -18.2% in previous quarter and historical rate -7.6%)
- EBITDA margin -500.0% decreased compared to -45.5% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0.0 bln (positive), 3.2% of market cap
- EV/Sales multiple is 5.2x
The company showed EPS -$3.28 per share
------------------------------------------------
#reports #SBRA
[Sabra Health Care](https://eninvs.com/all.php?name=SBRA) (Real estate investment fund) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169056)
(2024-05-08, After Market Close):
- Revenue +3.7% YoY (vs -1.2% in previous quarter and historical rate +3.2%)
- EBITDA +3.7% YoY (vs -1.2% in previous quarter and historical rate +41.9%)
- EBITDA margin 100.0% has not changed compared to 100.0% same period last year
- EV/EBITDA multiple is 8.8x compared to historical level (75th percentile) of 19.7x
- EV/Sales multiple is 8.7x
The company showed EPS +$0.11 per share. At the opening of the session the share price went down -0.8% vs S&P500 0.0%
------------------------------------------------
#reports #RGNX
[REGENXBIO](https://eninvs.com/all.php?name=RGNX) (Developer of viral gene therapy) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169091)
(2024-05-08, After Market Close):
- Revenue -15.8% YoY (vs -29.0% in previous quarter and historical rate +2.6%)
- EBITDA margin -375.0% decreased compared to -331.6% same period last year
- Net Debt decreased by $65.0 mln over the past reporting period (9.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 1.8% of market cap
- EV/Sales multiple is 4.9x
The company showed EPS -$1.38 per share. At the opening of the session the share price went down -0.7% vs S&P500 0.0%
------------------------------------------------
#reports #RCUS
[Arcus Biosciences](https://eninvs.com/all.php?name=RCUS) (Medicines developer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=RCUS&q=2024 q1&id=780470)
(2024-05-08, After Market Close):
- Revenue +480.0% YoY (vs -8.8% in previous quarter and historical rate +79.6%)
- EBITDA margin -9.7% increased compared to -336.0% same period last year
- Net Debt increased by $866.0 mln over the past reporting period (94.6% of market cap)
- FCF (LTM) -$0.2 bln (negative), 19.4% of market cap
- EV/Sales multiple is 0.2x
The company showed EPS -$0.05 per share. At the opening of the session the share price went up +11.1% vs S&P500 0.0%
------------------------------------------------
#reports #QRTEB
[Qurate Retail](https://eninvs.com/all.php?name=QRTEB) (Internet Retail) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169026)
(2024-05-08, Before Market Open):
- Revenue -11.4% YoY (vs +140.5% in previous quarter and historical rate -1.9%)
- EBITDA -11.6% YoY (vs -100.7% in previous quarter and historical rate -4.0%)
- EBITDA margin 10.4% has not changed compared to 10.4% same period last year
- Net Debt increased by $166.0 mln over the past reporting period (28.3% of market cap)
- FCF (LTM) +$0.4 bln (positive), 71.5% of market cap
- EV/EBITDA multiple is 7.2x compared to historical level (75th percentile) of 6.2x
- EV/Sales multiple is 0.7x
The company showed EPS -$0.00 per share. At the opening of the session the share price went up +11.2% vs S&P500 -0.4%
------------------------------------------------
#reports #PYCR
[Paycor HCM, Inc.](https://eninvs.com/all.php?name=PYCR) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168862)
(2024-05-08, After Market Close):
- Revenue +16.1% YoY (vs +20.3% in previous quarter and historical rate +25.0%)
- EBITDA +150.0% YoY (vs -1000.0% in previous quarter)
- EBITDA margin 5.3% increased compared to 2.5% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 0.7% of market cap
- EV/Sales multiple is 3.9x
The company showed EPS +$0.03 per share. At the opening of the session the share price went down -4.9% vs S&P500 0.0%
------------------------------------------------
#reports #PSNL
[Personalis](https://eninvs.com/all.php?name=PSNL) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169066)
(2024-05-08, After Market Close):
- Revenue +5.3% YoY (vs +17.6% in previous quarter and historical rate -0.2%)
- EBITDA margin -85.0% increased compared to -147.4% same period last year
- Net Debt increased by $13.0 mln over the past reporting period (16.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 55.2% of market cap
- EV/Sales multiple is 0.3x
The company showed EPS -$0.26 per share. At the opening of the session the share price went up +9.3% vs S&P500 0.0%
------------------------------------------------
#reports #NPCE
[NeuroPace, Inc.](https://eninvs.com/all.php?name=NPCE) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169067)
(2024-05-08, After Market Close):
- Revenue +28.6% YoY (vs +38.5% in previous quarter and historical rate +21.5%)
- EBITDA margin -38.9% increased compared to -57.1% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 1.4% of market cap
- EV/Sales multiple is 3.2x
The company showed EPS -$0.32 per share. At the opening of the session the share price went down -1.4% vs S&P500 0.0%
------------------------------------------------
#reports #NL
[NL Industries](https://eninvs.com/all.php?name=NL) (Security and Protection Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169206)
(2024-05-08, After Market Close):
- Revenue -7.3% YoY (vs +7.5% in previous quarter and historical rate +11.8%)
- EBITDA -68.2% YoY (vs +10.5% in previous quarter and historical rate +35.3%)
- EBITDA margin 18.4% decreased compared to 53.7% same period last year
- Net Debt increased by $142.0 mln over the past reporting period (36.9% of market cap)
- FCF (LTM) +$0.0 bln (positive), 2.3% of market cap
- EV/EBITDA multiple is 4.0x compared to historical level (75th percentile) of 3.8x
- EV/Sales multiple is 1.5x
The company showed EPS +$0.14 per share. At the opening of the session the share price went down -0.3% vs S&P500 0.0%
------------------------------------------------
#reports #MSEX
[Middlesex Water](https://eninvs.com/all.php?name=MSEX) (Water supply company) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169197)
(2024-05-08, After Market Close):
- Revenue +7.9% YoY (vs 0.0% in previous quarter and historical rate +6.1%)
- EBITDA +23.1% YoY (vs -11.8% in previous quarter and historical rate +8.3%)
- EBITDA margin 39.0% increased compared to 34.2% same period last year
- Net Debt increased by $377.0 mln over the past reporting period (36.7% of market cap)
- EV/EBITDA multiple is 20.7x compared to historical level (75th percentile) of 30.1x
- EV/Sales multiple is 8.3x
The company showed EPS +$0.60 per share. At the opening of the session the share price went up +3.6% vs S&P500 0.0%
------------------------------------------------
#reports #MRVI
[Maravai LifeSciences Holdings, Inc.](https://eninvs.com/all.php?name=MRVI) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=MRVI&q=2024 q1&id=780423)
(2024-05-08, After Market Close):
- Revenue -19.0% YoY (vs -63.9% in previous quarter and historical rate +3.5%)
- EBITDA margin -139.1% decreased compared to -86.1% same period last year
- EV/Sales multiple is 5.0x
The company showed EPS -$0.09 per share. At the opening of the session the share price went up +3.2% vs S&P500 0.0%
------------------------------------------------
#reports #MRUS
[Merus](https://eninvs.com/all.php?name=MRUS) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169112)
(2024-05-08, After Market Close):
- Revenue -38.5% YoY (vs -18.2% in previous quarter and historical rate +15.8%)
- EBITDA margin -575.0% decreased compared to -276.9% same period last year
- Net Debt increased by $17.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.1 bln (positive), 4.0% of market cap
- EV/Sales multiple is 54.3x
The company showed EPS -$0.59 per share. At the opening of the session the share price went up +0.1% vs S&P500 0.0%
------------------------------------------------
#reports #MRC
[MRC Global](https://eninvs.com/all.php?name=MRC) (Pipelines and components manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168725)
(2024-05-08, After Market Close):
- Revenue -8.9% YoY (vs -11.6% in previous quarter and historical rate +12.8%)
- EBITDA -28.4% YoY (vs -15.6% in previous quarter and historical rate +74.4%)
- EBITDA margin 6.0% decreased compared to 7.6% same period last year
- Net Debt decreased by $30.0 mln over the past reporting period (2.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 18.8% of market cap
- EV/EBITDA multiple is 9.0x compared to historical level (75th percentile) of 17.3x
- EV/Sales multiple is 0.6x
The company showed EPS +$0.22 per share. At the opening of the session the share price went up +4.9% vs S&P500 0.0%
------------------------------------------------
#reports #MNKD
[MannKind Corporation](https://eninvs.com/all.php?name=MNKD) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169246)
(2024-05-08, After Market Close):
- Revenue +61.0% YoY (vs +61.1% in previous quarter and historical rate +65.6%)
- EBITDA margin 27.3% increased compared to -9.8% same period last year
- Net Debt decreased by $11.0 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 13.4% of market cap
- EV/EBITDA multiple is 29.7x compared to historical level (75th percentile) of 80.1x
- EV/Sales multiple is 4.7x
The company showed EPS +$0.03 per share. At the opening of the session the share price went up +3.4% vs S&P500 0.0%
------------------------------------------------
#reports #LTRPB
[Liberty TripAdvisor](https://eninvs.com/all.php?name=LTRPB) (Internet Content and Information) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169098)
(2023-05-03):
- Revenue +6.5% YoY (vs +10.2% in previous quarter and historical rate +65.8%)
- EBITDA 0.0% YoY (vs +562.5% in previous quarter and historical rate +54.8%)
- EBITDA margin 1.0% has not changed compared to 1.1% same period last year
- Net Debt decreased by $98.0 mln over the past reporting period (223.4% of market cap)
- FCF (LTM) +$0.7 bln (positive), 1598.1% of market cap
- EV/Sales multiple is 1.1x
The company showed EPS -$0.85 per share
------------------------------------------------
#reports #LBRDK
[Liberty Broadband (K)](https://eninvs.com/all.php?name=LBRDK) ( Multinational telecommunications company) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169102)
(2024-05-08, Before Market Open):
- Revenue -0.4% YoY (vs 0.0% in previous quarter and historical rate +49.7%)
- EBITDA +5.4% YoY (vs +117.6% in previous quarter and historical rate +69.4%)
- EBITDA margin 31.8% increased compared to 30.1% same period last year
- Net Debt decreased by $50.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.8% of market cap
- EV/EBITDA multiple is 41.1x compared to historical level (75th percentile) of 77.3x
- EV/Sales multiple is 12.7x
The company showed EPS +$1.69 per share. At the opening of the session the share price went down -0.5% vs S&P500 -0.4%
------------------------------------------------
#reports #HUBS
[HubSpot](https://eninvs.com/all.php?name=HUBS) (Platform for marketing and sales) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168524)
(2024-05-08, After Market Close):
- Revenue +22.9% YoY (vs +23.8% in previous quarter and historical rate +33.9%)
- EBITDA margin -1.3% increased compared to -5.6% same period last year
- Net Debt decreased by $145.0 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0.1 bln (negative), 0.3% of market cap
- EV/Sales multiple is 12.2x
The company showed EPS +$0.12 per share. At the opening of the session the share price went up +5.9% vs S&P500 0.0%
------------------------------------------------
#reports #HNST
[The Honest Company, Inc.](https://eninvs.com/all.php?name=HNST) (Specialty Retail) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=HNST&q=2024 q1&id=780369)
(2024-05-08, After Market Close):
- Revenue +3.6% YoY (vs +9.8% in previous quarter and historical rate +4.0%)
- EBITDA margin -1.2% increased compared to -21.7% same period last year
- Net Debt decreased by $3.0 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 9.9% of market cap
- EV/Sales multiple is 0.8x
The company showed EPS -$0.01 per share. At the opening of the session the share price went up +1.7% vs S&P500 0.0%
------------------------------------------------
#reports #HCI
[HCI Group](https://eninvs.com/all.php?name=HCI) (Insurance services provider) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168713)
(2024-05-08, After Market Close):
- Revenue +60.5% YoY (vs +35.8% in previous quarter and historical rate +27.4%)
- Net Income +216.7% YoY (vs +1266.7% in previous quarter and historical rate +46.3%)
- Net Income margin 27.5% increased compared to 14.0% same period last year
- P/E multiple is 7.3x compared to historical level (75th percentile) of 107.2x
- P/S multiple is 1.5x
- Price to book: 2.4x
The company showed EPS +$3.68 per share. At the opening of the session the share price went up +3.7% vs S&P500 0.0%
------------------------------------------------
#reports #GMRE
[Global Medical REIT](https://eninvs.com/all.php?name=GMRE) (REIT — Healthcare Facilities) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169070)
(2024-05-07, After Market Close):
- Revenue -2.8% YoY (vs -8.3% in previous quarter and historical rate +12.8%)
- EBITDA -5.0% YoY (vs -9.5% in previous quarter and historical rate +24.8%)
- EBITDA margin 54.3% decreased compared to 55.6% same period last year
- EV/EBITDA multiple is 16.2x compared to historical level (75th percentile) of 23.6x
- EV/Sales multiple is 9.0x
The company showed EPS +$0.01 per share. At the opening of the session the share price went down -0.4% vs S&P500 -0.4%
------------------------------------------------
#reports #GLP
[Global Partners LP](https://eninvs.com/all.php?name=GLP) (Oil and Gas Midstream) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169020)
(2024-05-08, Before Market Open):
- Revenue +2.9% YoY (vs -0.4% in previous quarter and historical rate +34.3%)
- EBITDA +7.4% YoY (vs -46.7% in previous quarter and historical rate +24.3%)
- EBITDA margin 1.4% has not changed compared to 1.3% same period last year
- Net Debt increased by $225.0 mln over the past reporting period (15.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 1.9% of market cap
- EV/EBITDA multiple is 9.5x compared to historical level (75th percentile) of 9.5x
- EV/Sales multiple is 0.2x
The company showed EPS -$0.26 per share. At the opening of the session the share price went down -9.4% vs S&P500 -0.4%
------------------------------------------------
#reports #FRAF
[Franklin Financial Services Corporation](https://eninvs.com/all.php?name=FRAF) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169207)
(2023-04-25, Before Market Open):
- Revenue +7.7% YoY (vs 0.0% in previous quarter and historical rate +8.9%)
- Net Income margin 21.4% increased compared to -7.7% same period last year
- P/E multiple is 7.2x compared to historical level (75th percentile) of 11.2x
- P/S multiple is 1.7x
- Price to book: 0.9x
The company showed EPS +$0.77 per share. At the opening of the session the share price went up +0.5% vs S&P500 -0.3%
------------------------------------------------
#reports #FNA
[Paragon 28, Inc.](https://eninvs.com/all.php?name=FNA) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169069)
(2024-05-08, After Market Close):
- Revenue +17.3% YoY (vs +17.3% in previous quarter and historical rate +46.6%)
- EBITDA margin -14.8% decreased compared to -9.6% same period last year
- Net Debt increased by $17.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) -$0.1 bln (negative), 14.9% of market cap
- EV/Sales multiple is 3.0x
The company showed EPS -$0.18 per share. At the opening of the session the share price went down -8.7% vs S&P500 0.0%
------------------------------------------------
#reports #ESTA
[Establishment Labs](https://eninvs.com/all.php?name=ESTA) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=ESTA&q=2024 q1&id=780336)
(2024-05-08, After Market Close):
- Revenue -21.3% YoY (vs -27.3% in previous quarter and historical rate +30.4%)
- EBITDA margin -16.2% decreased compared to -10.6% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 0.8% of market cap
- EV/Sales multiple is 10.1x
The company showed EPS -$0.58 per share. At the opening of the session the share price went up +6.1% vs S&P500 0.0%
------------------------------------------------
#reports #ENV
[Envestnet](https://eninvs.com/all.php?name=ENV) (Software for financial advisors creator) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169024)
(2024-05-07, After Market Close):
- Revenue -3.0% YoY (vs -43.0% in previous quarter and historical rate +2.7%)
- EBITDA +200.0% YoY (vs +16300.0% in previous quarter and historical rate +29.3%)
- EBITDA margin 22.8% increased compared to 7.4% same period last year
- Net Debt decreased by $905.0 mln over the past reporting period (24.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 2.5% of market cap
- EV/EBITDA multiple is 16.1x compared to historical level (75th percentile) of 64.9x
- EV/Sales multiple is 4.2x
The company showed EPS +$0.05 per share. At the opening of the session the share price went up +2.0% vs S&P500 -0.4%
------------------------------------------------
#reports #EMKR
[EMCORE Corporation](https://eninvs.com/all.php?name=EMKR) (Semiconductors) reported for 2024 q1
(2024-05-02, After Market Close):
- Revenue -25.9% YoY (vs -4.0% in previous quarter and historical rate -1.3%)
- EBITDA margin -45.0% decreased compared to -40.7% same period last year
- Net Debt increased by $9.0 mln over the past reporting period (96.3% of market cap)
- FCF (LTM) +$0.0 bln (positive), 32.1% of market cap
- EV/Sales multiple is 0.3x
The company showed EPS -$0.95 per share. At the opening of the session the share price went up +1.6% vs S&P500 +1.2%
------------------------------------------------
#reports #ECOR
[electroCore](https://eninvs.com/all.php?name=ECOR) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169080)
(2023-05-17, After Market Close):
- Revenue +66.7% YoY (vs +66.7% in previous quarter and historical rate +94.4%)
- EBITDA margin -80.0% increased compared to -200.0% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (12.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 6.2% of market cap
- EV/Sales multiple is 1.4x
The company showed EPS -$0.53 per share. At the opening of the session the share price went up +0.1% vs S&P500 0.0%
------------------------------------------------
#reports #DUOL
[Duolingo, Inc.](https://eninvs.com/all.php?name=DUOL) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DUOL&q=2024 q1&id=780322)
(2024-05-08, After Market Close):
- Revenue +44.8% YoY (vs +45.2% in previous quarter and historical rate +41.9%)
- EBITDA margin 11.3% increased compared to -6.0% same period last year
- Net Debt decreased by $49.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.2 bln (positive), 2.1% of market cap
- EV/Sales multiple is 12.2x
The company showed EPS +$0.57 per share. At the opening of the session the share price went down -17.8% vs S&P500 0.0%
------------------------------------------------
#reports #DDI
[DoubleDown Interactive Co., Ltd.](https://eninvs.com/all.php?name=DDI) (Electronic Gaming and Multimedia) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DDI&q=2024 q1&id=780307)
(2024-05-08, After Market Close):
- Revenue +12.8% YoY (vs +9.2% in previous quarter and historical rate -5.4%)
- EBITDA +28.0% YoY (vs +3500.0% in previous quarter and historical rate +1.1%)
- EBITDA margin 36.4% increased compared to 32.1% same period last year
- Net Debt decreased by $266.0 mln over the past reporting period (42.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 5.0% of market cap
- EV/EBITDA multiple is 2.8x compared to historical level (75th percentile) of 5.4x
- EV/Sales multiple is 1.1x
The company showed EPS +$0.61 per share. At the opening of the session the share price went up +2.4% vs S&P500 0.0%
------------------------------------------------
#reports #CTLT
[Catalent](https://eninvs.com/all.php?name=CTLT) (Medicines developer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169094)
(2024-05-02, Before Market Open):
- Revenue +3.6% YoY (vs -10.2% in previous quarter and historical rate +4.7%)
- EBITDA margin 8.0% increased compared to -12.7% same period last year
- Net Debt increased by $68.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.5 bln (positive), 5.2% of market cap
- EV/Sales multiple is 2.4x
The company showed EPS -$0.55 per share. At the opening of the session the share price went up +0.6% vs S&P500 +0.6%
------------------------------------------------
#reports #CTKB
[Cytek Biosciences, Inc.](https://eninvs.com/all.php?name=CTKB) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169155)
(2024-05-08, After Market Close):
- Revenue +21.6% YoY (vs +22.9% in previous quarter and historical rate +20.8%)
- EBITDA margin -20.0% increased compared to -29.7% same period last year
- Net Debt decreased by $1.5 bln over the past reporting period (180.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.0% of market cap
- EV/Sales multiple is 2.9x
The company showed EPS -$0.05 per share. At the opening of the session the share price went up +1.3% vs S&P500 0.0%
------------------------------------------------
#reports #CR
[Crane](https://eninvs.com/all.php?name=CR) (Engineering industrial products manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169183)
(2024-04-22, After Market Close):
- Revenue -4.6% YoY (vs -56.7% in previous quarter and historical rate -15.8%)
- EBITDA -16.0% YoY (vs -0.6% in previous quarter and historical rate +3.5%)
- EBITDA margin 25.2% decreased compared to 28.6% same period last year
- Net Debt decreased by $386.0 mln over the past reporting period (4.8% of market cap)
- FCF (LTM) +$0.6 bln (positive), 6.9% of market cap
- EV/EBITDA multiple is 20.2x compared to historical level (75th percentile) of 16.4x
- EV/Sales multiple is 5.9x
The company showed EPS +$1.12 per share. At the opening of the session the share price went up +3.9% vs S&P500 +0.4%
------------------------------------------------
#reports #CPRX
[Catalyst Pharmaceuticals](https://eninvs.com/all.php?name=CPRX) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169030)
(2024-05-08, After Market Close):
- Revenue +16.5% YoY (vs +82.0% in previous quarter and historical rate +54.7%)
- EBITDA -22.9% YoY (vs +35.5% in previous quarter and historical rate +41.1%)
- EBITDA margin 27.3% decreased compared to 41.2% same period last year
- Net Debt decreased by $173.0 mln over the past reporting period (10.2% of market cap)
- FCF (LTM) +$0.2 bln (positive), 9.1% of market cap
- EV/EBITDA multiple is 17.8x compared to historical level (75th percentile) of 16.6x
- EV/Sales multiple is 3.4x
The company showed EPS +$0.19 per share. At the opening of the session the share price went up +1.0% vs S&P500 0.0%
------------------------------------------------
#reports #CPK
[Chesapeake Utilities Corporation](https://eninvs.com/all.php?name=CPK) (Utilities — Regulated Gas) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169179)
(2024-05-08, After Market Close):
- Revenue +12.8% YoY (vs -1.1% in previous quarter and historical rate +10.5%)
- EBITDA +34.7% YoY (vs +32.6% in previous quarter and historical rate +11.6%)
- EBITDA margin 39.4% increased compared to 33.0% same period last year
- Net Debt decreased by $4.0 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) -$0.6 bln (negative), 27.4% of market cap
- EV/EBITDA multiple is 14.6x compared to historical level (75th percentile) of 15.6x
- EV/Sales multiple is 5.2x
The company showed EPS +$2.07 per share. At the opening of the session the share price went down -0.7% vs S&P500 0.0%
------------------------------------------------
#reports #COOK
[Traeger, Inc.](https://eninvs.com/all.php?name=COOK) (Furnishings, Fixtures and Appliances) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=COOK&q=2024 q1&id=780295)
(2024-05-08, After Market Close):
- Revenue -5.2% YoY (vs +18.1% in previous quarter and historical rate -5.1%)
- Net Debt increased by $18.0 mln over the past reporting period (6.2% of market cap)
- FCF (LTM) +$0.0 bln (positive), 10.3% of market cap
- EV/Sales multiple is 1.2x
The company showed EPS -$0.04 per share. At the opening of the session the share price went down -0.4% vs S&P500 0.0%
------------------------------------------------
#reports #CDXC
[ChromaDex Corporation](https://eninvs.com/all.php?name=CDXC) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=CDXC&q=2024 q1&id=780288)
(2024-05-08, After Market Close):
- Revenue -4.3% YoY (vs 0.0% in previous quarter and historical rate +12.8%)
- EV/Sales multiple is 3.2x
The company showed EPS -$0.01 per share. At the opening of the session the share price went down -5.7% vs S&P500 0.0%
------------------------------------------------
#reports #CDLX
[Cardlytics](https://eninvs.com/all.php?name=CDLX) (Marketing services provider ) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169114)
(2024-03-14, After Market Close):
- Revenue +6.3% YoY (vs +7.2% in previous quarter and historical rate +22.1%)
- EBITDA -189.5% YoY (vs -9700.0% in previous quarter and historical rate -1.9%)
- EBITDA margin -25.0% decreased compared to 29.7% same period last year
- Net Debt decreased by $174.0 mln over the past reporting period (50.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 13.5% of market cap
- EV/Sales multiple is 1.7x
The company showed EPS -$0.56 per share. At the opening of the session the share price went up +52.7% vs S&P500 -0.5%
------------------------------------------------
#reports #CAKE
[Cheesecake Factory](https://eninvs.com/all.php?name=CAKE) (Restaurants) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169242)
(2024-05-08, After Market Close):
- Revenue +2.9% YoY (vs -1.8% in previous quarter and historical rate +26.6%)
- EBITDA +68.4% YoY (vs +300.0% in previous quarter and historical rate +46.9%)
- EBITDA margin 10.8% increased compared to 6.6% same period last year
- Net Debt increased by $1.8 bln over the past reporting period (100.0% of market cap)
- EV/EBITDA multiple is 15.2x compared to historical level (75th percentile) of 14.8x
- EV/Sales multiple is 1.0x
The company showed EPS +$0.68 per share. At the opening of the session the share price went up +7.4% vs S&P500 0.0%
------------------------------------------------
#reports #BYND
[Beyond Meat](https://eninvs.com/all.php?name=BYND) (Food products provider) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BYND&q=2024 q1&id=780283)
(2024-05-08, After Market Close):
- Revenue -17.4% YoY (vs -7.5% in previous quarter and historical rate -6.7%)
- EBITDA margin -61.8% decreased compared to -56.5% same period last year
- Net Debt increased by $37.0 mln over the past reporting period (8.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 30.3% of market cap
- EV/Sales multiple is 4.7x
The company showed EPS -$0.84 per share. At the opening of the session the share price went down -14.4% vs S&P500 0.0%
------------------------------------------------
#reports #BLZE
[Backblaze, Inc.](https://eninvs.com/all.php?name=BLZE) (Software — Infrastructure) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BLZE&q=2024 q1&id=780279)
(2024-05-08, After Market Close):
- Revenue +30.4% YoY (vs +26.1% in previous quarter and historical rate +23.0%)
- EBITDA margin -13.3% increased compared to -47.8% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 7.9% of market cap
- EV/Sales multiple is 2.3x
The company showed EPS -$0.27 per share. At the opening of the session the share price went down -9.2% vs S&P500 0.0%
Country: UNITED STATES
Sector: Electronic Components
Quarterly values ($m)
Change (y/y)
FCF ($m)
Net Debt / Cash and Equivalents ($m)
EV / EBITDA
Potential dynamics
Property | 2024 q1 | 2023 q4 | 2023 q3 | 2023 q2 | 2023 q1 | 2022 q4 | 2022 q3 |
---|---|---|---|---|---|---|---|
date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
symbol | BELFB | BELFB | BELFB | BELFB | BELFB | BELFB | BELFB |
reportedCurrency | USD | USD | USD | USD | USD | USD | USD |
cik | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 |
fillingDate | 2024-04-30 | 2024-03-11 | 2023-11-03 | 2023-08-04 | 2023-05-05 | 2023-03-10 | 2022-11-04 |
acceptedDate | 2024-04-30 11:17:41 | 2024-03-11 08:27:05 | 2023-11-03 12:49:53 | 2023-08-04 13:25:51 | 2023-05-05 12:44:13 | 2023-03-10 16:13:19 | 2022-11-04 15:14:12 |
calendarYear | 2024.000 | 2023.000 | 2023.000 | 2023.000 | 2023.000 | 2022.000 | 2022.000 |
period | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 |
revenue | 128M | 140M | 159M | 169M | 172M | 169M | 178M |
costOfRevenue | 80M | 89M | 103M | 113M | 119M | 117M | 126M |
grossProfit | 48M | 51M | 55M | 56M | 54M | 53M | 52M |
grossProfitRatio | 0.375 | 0.366 | 0.350 | 0.329 | 0.311 | 0.310 | 0.290 |
researchAndDevelopmentExpenses | 5M | 6M | 5M | 6M | 5M | 6M | 5M |
generalAndAdministrativeExpenses | 0 | 25M | 0 | 25M | 0 | 22M | 22M |
sellingAndMarketingExpenses | 0 | -193 000 | 0 | 0 | 0 | 3M | 0 |
sellingGeneralAndAdministrativeExpenses | 25M | 25M | 24M | 25M | 25M | 25M | 22M |
otherExpenses | 2M | -3M | -96 000 | -270 000 | 81 000 | 0 | 0 |
operatingExpenses | 30M | 31M | 29M | 31M | 31M | 31M | 27M |
costAndExpenses | 110M | 120M | 132M | 144M | 149M | 148M | 153M |
interestIncome | 1M | -2M | 512 000 | 0 | 0 | 0 | 0 |
interestExpense | 434 000 | 448 000 | 512 000 | 908 000 | 983 000 | 968 000 | 944 000 |
depreciationAndAmortization | 4M | 3M | 3M | 3M | 7M | 4M | 3M |
ebitda | 22M | 24M | 30M | 27M | 26M | 22M | 25M |
ebitdaratio | 0.169 | 0.169 | 0.187 | 0.163 | 0.154 | 0.128 | 0.140 |
operatingIncome | 18M | 20M | 25M | 27M | 20M | 18M | 22M |
operatingIncomeRatio | 0.140 | 0.145 | 0.154 | 0.162 | 0.114 | 0.108 | 0.124 |
totalOtherIncomeExpensesNet | 2M | -7M | -2M | 4M | -902 000 | -750 000 | -1M |
incomeBeforeTax | 20M | 13M | 24M | 27M | 19M | 17M | 21M |
incomeBeforeTaxRatio | 0.159 | 0.096 | 0.150 | 0.162 | 0.109 | 0.103 | 0.116 |
incomeTaxExpense | 4M | 1M | 4M | -479 000 | 4M | 3M | 4M |
netIncome | 16M | 12M | 19M | 28M | 15M | 14M | 17M |
netIncomeRatio | 0.124 | 0.086 | 0.123 | 0.165 | 0.085 | 0.083 | 0.093 |
eps | 1.120 | 0.950 | 1.460 | 2.190 | 1.090 | 1.120 | 1.270 |
epsdiluted | 1.120 | 0.950 | 1.460 | 2.190 | 1.090 | 1.120 | 1.270 |
weightedAverageShsOut | 14M | 13M | 13M | 13M | 2M | 13M | 12M |
weightedAverageShsOutDil | 14M | 13M | 13M | 13M | 11M | 13M | 12M |
link | Link | Link | Link | Link | Link | Link | Link |
finalLink | Link | Link | Link | Link | Link | Link | Link |
Property | 2024 q1 | 2023 q4 | 2023 q3 | 2023 q2 | 2023 q1 | 2022 q4 | 2022 q3 |
---|---|---|---|---|---|---|---|
date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
symbol | BELFB | BELFB | BELFB | BELFB | BELFB | BELFB | BELFB |
reportedCurrency | USD | USD | USD | USD | USD | USD | USD |
cik | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 |
fillingDate | 2024-04-30 | 2024-03-11 | 2023-11-03 | 2023-08-04 | 2023-05-05 | 2023-03-10 | 2022-11-04 |
acceptedDate | 2024-04-30 11:17:41 | 2024-03-11 08:27:05 | 2023-11-03 12:49:53 | 2023-08-04 13:25:51 | 2023-05-05 12:44:13 | 2023-03-10 16:13:19 | 2022-11-04 15:14:12 |
calendarYear | 2024.000 | 2023.000 | 2023.000 | 2023.000 | 2023.000 | 2022.000 | 2022.000 |
period | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 |
cashAndCashEquivalents | 71M | 89M | 100M | 65M | 78M | 70M | 71M |
shortTermInvestments | 50M | 38M | 0 | 0 | 0 | 0 | 0 |
cashAndShortTermInvestments | 121M | 127M | 100M | 65M | 78M | 70M | 71M |
netReceivables | 83M | 97M | 94M | 107M | 109M | 107M | 132M |
inventory | 130M | 137M | 140M | 157M | 166M | 172M | 164M |
otherCurrentAssets | 29M | 21M | 29M | 25M | 30M | 31M | 10M |
totalCurrentAssets | 364M | 381M | 363M | 354M | 383M | 381M | 377M |
propertyPlantEquipmentNet | 57M | 57M | 60M | 61M | 59M | 58M | 56M |
goodwill | 25M | 27M | 25M | 26M | 25M | 25M | 24M |
intangibleAssets | 48M | 49M | 51M | 52M | 53M | 54M | 55M |
goodwillAndIntangibleAssets | 73M | 76M | 76M | 78M | 79M | 79M | 79M |
longTermInvestments | 13M | 16M | 10M | 11M | 10M | 0 | 0 |
taxAssets | 13M | 12M | 2M | 2M | 8M | 7M | 9M |
otherNonCurrentAssets | 34M | 29M | 48M | 46M | 36M | 34M | 33M |
totalNonCurrentAssets | 191M | 190M | 196M | 198M | 192M | 179M | 176M |
otherAssets | 0 | 1.000 | 0 | 0 | 0 | 0 | 0 |
totalAssets | 555M | 572M | 559M | 552M | 575M | 560M | 554M |
accountPayables | 33M | 40M | 44M | 52M | 60M | 65M | 66M |
shortTermDebt | 6M | 7M | 6M | 6M | 5M | 6M | 6M |
taxPayables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
deferredRevenue | 3M | 3M | 3M | 4M | 7M | 9M | 0 |
otherCurrentLiabilities | 45M | 60M | 65M | 65M | 57M | 57M | 65M |
totalCurrentLiabilities | 87M | 111M | 118M | 127M | 130M | 136M | 137M |
longTermDebt | 60M | 60M | 76M | 77M | 115M | 111M | 125M |
deferredRevenueNonCurrent | 14M | 16M | -973 000 | -1M | 0 | 1M | 0 |
deferredTaxLiabilitiesNonCurrent | 1M | 1M | 973 000 | 1M | 1M | 1M | 1M |
otherNonCurrentLiabilities | 46M | 43M | 44M | 44M | 50M | 49M | 109M |
totalNonCurrentLiabilities | 122M | 120M | 120M | 121M | 167M | 162M | 181M |
otherLiabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
capitalLeaseObligations | 16M | 16M | 22M | 23M | 20M | 22M | 21M |
totalLiabilities | 209M | 231M | 238M | 248M | 296M | 298M | 318M |
preferredStock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
commonStock | 1M | 1M | 1M | 1M | 1M | 1M | 1M |
retainedEarnings | 323M | 308M | 296M | 278M | 251M | 237M | 224M |
accumulatedOtherComprehensiveIncomeLoss | -15M | -12M | -19M | -17M | -15M | -17M | -29M |
othertotalStockholdersEquity | 38M | 44M | 43M | 42M | 41M | 40M | 40M |
totalStockholdersEquity | 347M | 341M | 321M | 304M | 278M | 262M | 236M |
totalEquity | 347M | 341M | 321M | 304M | 278M | 262M | 236M |
totalLiabilitiesAndStockholdersEquity | 555M | 572M | 559M | 552M | 575M | 560M | 554M |
minorityInterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
totalLiabilitiesAndTotalEquity | 555M | 572M | 559M | 552M | 575M | 560M | 554M |
totalInvestments | 63M | 54M | 10M | 11M | 10M | 0 | 0 |
totalDebt | 81M | 83M | 82M | 83M | 120M | 117M | 131M |
netDebt | 10M | -7M | -18M | 18M | 42M | 46M | 60M |
link | Link | Link | Link | Link | Link | Link | Link |
finalLink | Link | Link | Link | Link | Link | Link | Link |
Property | 2024 q1 | 2023 q4 | 2023 q3 | 2023 q2 | 2023 q1 | 2022 q4 | 2022 q3 |
---|---|---|---|---|---|---|---|
date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
symbol | BELFB | BELFB | BELFB | BELFB | BELFB | BELFB | BELFB |
reportedCurrency | USD | USD | USD | USD | USD | USD | USD |
cik | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 | 729 580 |
fillingDate | 2024-04-30 | 2024-03-11 | 2023-11-03 | 2023-08-04 | 2023-05-05 | 2023-03-10 | 2022-11-04 |
acceptedDate | 2024-04-30 11:17:41 | 2024-03-11 08:27:05 | 2023-11-03 12:49:53 | 2023-08-04 13:25:51 | 2023-05-05 12:44:13 | 2023-03-10 16:13:19 | 2022-11-04 15:14:12 |
calendarYear | 2024.000 | 2023.000 | 2023.000 | 2023.000 | 2023.000 | 2022.000 | 2022.000 |
period | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 |
netIncome | 16M | 12M | 19M | 28M | 15M | 14M | 17M |
depreciationAndAmortization | 4M | 3M | 3M | 3M | 3M | 3M | 3M |
deferredIncomeTax | -2M | 1M | -2M | -2M | -1M | 519 000 | -2M |
stockBasedCompensation | 804 000 | 774 000 | 861 000 | 949 000 | 902 000 | 710 000 | 585 000 |
changeInWorkingCapital | -12M | 7M | 19M | -177 000 | -1M | -3M | -4M |
accountsReceivables | 4M | 14M | 12M | 1M | -1M | -3M | -5M |
inventory | 6M | 4M | 16M | 6M | 8M | -4M | -7M |
accountsPayables | -8M | -4M | -7M | -7M | -5M | -3M | -1M |
otherWorkingCapital | -14M | -7M | -2M | -365 000 | -3M | 7M | 10M |
otherNonCashItems | 5M | 2M | 242 000 | -6M | 697 000 | 1M | -1M |
netCashProvidedByOperatingActivities | 6M | 27M | 41M | 24M | 17M | 16M | 13M |
investmentsInPropertyPlantAndEquipment | -3M | -2M | -3M | -3M | -4M | -3M | -2M |
acquisitionsNet | 150 000 | 633 000 | -135 000 | 5M | -10M | 0 | 0 |
purchasesOfInvestments | -43M | -61M | -2M | 0 | 0 | 0 | 0 |
salesMaturitiesOfInvestments | 30M | 20M | 2M | 0 | 0 | 0 | 0 |
otherInvestingActivites | -492 000 | -247 000 | -2M | 5M | 25 000 | 0 | 2M |
netCashUsedForInvestingActivites | -16M | -42M | -4M | 7M | -14M | -3M | -320 000 |
debtRepayment | 0 | -45M | 0 | 0 | 0 | -15M | -3M |
commonStockIssued | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
commonStockRepurchased | -6M | -105 000 | 0 | 0 | 0 | 349 000 | 0 |
dividendsPaid | -837 000 | -1M | -832 000 | -829 000 | -829 000 | -943 000 | -824 000 |
otherFinancingActivites | 0 | 85M | 0 | -40M | 5M | -349 000 | 0 |
netCashUsedProvidedByFinancingActivities | -7M | -1M | -832 000 | -41M | 4M | -16M | -3M |
effectOfForexChangesOnCash | -2M | 6M | -311 000 | -3M | 279 000 | 2M | -4M |
netChangeInCash | -18M | -11M | 35M | -13M | 8M | -629 000 | 5M |
cashAtEndOfPeriod | 71M | 89M | 100M | 65M | 78M | 70M | 71M |
cashAtBeginningOfPeriod | 89M | 100M | 65M | 78M | 70M | 71M | 66M |
operatingCashFlow | 6M | 27M | 41M | 24M | 17M | 16M | 13M |
capitalExpenditure | -3M | -2M | -3M | -3M | -4M | -3M | -2M |
freeCashFlow | 3M | 24M | 38M | 21M | 13M | 13M | 11M |
link | Link | Link | Link | Link | Link | Link | Link |
finalLink | Link | Link | Link | Link | Link | Link | Link |
Show financial reports only
Show all press releases
Show financial reports only
Show all press releases
Show financial reports only
Show all press releases
Show financial reports only
Show all press releases